[ Carol, chat MABXA ]
Releases like this really seem to be moving some biotechs. Don't know why.... it's just shameful promo.
I haven't looked at them in a long time. They were making a big deal out of an antibody that was supposed to be diagnostic for a heart attack a few years ago, but it looks like they have failed to thrive.
A track record of hype/BS...... they have a patent issued for making monoclonal antibodies in specific pathogen free mice. Some data indicates that many antibodies are derived at a higher frequency. My reaction was always..... "who cares? The frequency with which you derive monoclonals in normal mice is sufficient, and an extra spleen will cost you another $10." They used to pound and pound and pound on that patent, making it virtually the core of the business plan. I just always said "huh?"
They've been around for a long, long time, Carol. Don't know if there's still a close affiliation, but they sort of derived from Notre Dame. My first blush is always negative when I hear anything about them, and it's been predictive thus far. I haven't taken a look in a long time, however, so..... grain of salt.
Carol/Ray/Ranier.... you might want to put BTRN on your watch list. Great science, and a partnered project with Medimmune, for at least 10% royalties, that addresses really nice sized markets. Currently selling for at zero research premium (that is, the market cap is equal to cash in-hand). No reason to believe that it will move near-term.
Leaving tomorrow for a week in the Sierras with the kids...... no time to breathe.
Cheers! Rick |
